Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.Materials and Methods Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.Results Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).Conclusion Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.
Abstract
Purpose In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.Materials and Methods Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.Results Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).Conclusion Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.
참고문헌 (25)
- Siegel RL, "Cancer statistics, 2022", CA Cancer J Clin, 72, pp.7~33 (2022)
- Lorente D, "Optimal treatment sequence for metastatic castration-resistant prostate cancer", Eur Urol Focus, 2, pp.488~498 (2016)
- do Pazo C, "The prostate cancer drug market", Nat Rev Drug Discov, 20, pp.663~664 (2021)
- Scher HI, "Increased survival with enzalutamide in prostate cancer after chemotherapy", N Engl J Med, 367, pp.1187~1197 (2012)
- Beer TM, "Enzalutamide in metastatic prostate cancer before chemotherapy", N Engl J Med, 371, pp.424~433 (2014)
- Kim CS, "The PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic castration-resistant prostate cancer : post hoc analysis of Korean patients", Investig Clin Urol, 57, pp.174~183 (2016)
- Isensee G, "Is there a flare phenomenon on bone scintigraphy in men with advanced prostate cancer treated with radium-223?", Clin Genitourin Cancer, 16, pp.349~354 (2018)
- Sonpavde G, "Radiographic progression by Prostate Cancer Working Group(PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer", BJU Int, 114, pp.E25~E31 (2014)
- Pollen JJ, "Osteoblastic response to successful treatment of metastatic cancer of the prostate", AJR Am J Roentgenol, 132, pp.927~931 (1979)
- Coleman RE, "Bone scan flare predicts successful systemic therapy for bone metastases", J Nucl Med, 29, pp.1354~1359 (1988)
- Ryan CJ, "Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response", Clin Cancer Res, 17, pp.4854~4861 (2011)
- Conteduca V, "Flare phenomenon in prostate cancer : recent evidence on new drugs and next generation imaging", Ther Adv Med Oncol, 13, pp.1758835920987654~ (2021)
- Armstrong AJ, "Association between new unconfirmed bone lesions and outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide : secondary analysis of the PREVAIL and AFFIRM randomized clinical trials", JAMA Oncol, 6, pp.217~225 (2020)
- Jung SI, "Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer : a retrospective Korean multicenter study in a real-world setting", Investig Clin Urol, 61, pp.19~27 (2020)
- Jeong CW, "Importance of androgen-deprivation therapy during enzalutamide treatment in men with metastatic castration-resistant prostate cancer following chemotherapy : results from retrospective, multicenter data", Prostate Cancer Prostatic Dis, 22, pp.150~158 (2019)
- Harris PA, "Research electronic data capture(REDCap) : a metadatadriven methodology and workflow process for providing translational research informatics support", J Biomed Inform, 42, pp.377~381 (2009)
- Scher HI, "Trial design and objectives for castration-resistant prostate cancer : updated recommendations from the Prostate Cancer Clinical Trials Working Group 3", J Clin Oncol, 34, pp.1402~1418 (2016)
- Scher HI, "Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone : recommendations of the Prostate Cancer Clinical Trials Working Group", J Clin Oncol, 26, pp.1148~1159 (2008)
- Anand A, "Automated bone scan index to optimize Prostate Cancer Working Group radiographic progression criteria for men with metastatic castration-resistant prostate cancer", Clin Genitourin Cancer, 20, pp.270~277 (2022)
- Kim CS, "Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer", Medicine(Baltimore), 96, pp.e7223~ (2017)
- Fletcher SA, "Contemporary national trends in prostate cancer risk profile at diagnosis", Prostate Cancer Prostatic Dis, 23, pp.81~87 (2020)
- Wallace KL, "Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States", Cancer Causes Control, 32, pp.1365~1374 (2021)
- Ryan C, "Epidemiology of bone metastases", Bone, 158, pp.115783~ (2022)
- Negoita S, "Annual report to the nation on the status of cancer, part II : recent changes in prostate cancer trends and disease characteristics", Cancer, 124, pp.2801~2814 (2018)
- Simsek DH, "Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET", CT in prostate cancer?, 2020, pp.34, 476~485